Invasive mucormycosis is an uncommon but increasing life-threatening fungal infection. The present study investigated clinical characteristics and mortality among patients diagnosed as invasive mucormycosis infection. We retrospectively reviewed a total of 24 histologically proven cases of invasive mucormycosis at two tertiary care referral hospitals between November 2005 and February 2014. Overall survival was 50% (n = 12). The time between onset of symptom and diagnostic procedure proved to be associated with mortality (P = 0.009). In addition, preexisting renal failure and thrombocytopenia demonstrated trends toward a poor outcome in our study (P = 0.089 and 0.065, respectively). On multivariate regression analysis, delayed diagnostic procedure (more than 16 days after the onset of symptoms) was an independent predictor of mortality (OR= 12.34, 95% CI, 1.43-10.64; P = 0.022). Mucormycosis is a destructive fungal infection that is associated with high mortality rates, ranging from 40% to 100% depending on the form of disease. When a clinician suspects invasive mucormycosis infection, an early diagnostic procedure performed within 16 days from the onset of symptom and early initiation of antifungal therapy will lead to successful management of this highly fatal disease.
Introduction
Mucormycosis is a relatively uncommon, but destructive fungal infection which occurs predominantly in immunocompromised patients, especially among those with haematologic malignancies and transplant recipients. 1, 2 Immunocompetent patients with diabetes mellitus, subcutaneous tissue injury, iron overload and those treated with deferoxamine therapy are also at risk for infection. 3, 4 There are no currently available antigen assays to screen for mucormycosis infection, 5 and definitive diagnosis of mucormycosis requires direct sampling of infected tissue. 2 Early antifungal treatment and surgical excision are the cornerstones of mucormycosis infection treatment. 1 Amphotericin B (AmB) has been the most active antifungal agent in treating mucormycosis infection. AmB deoxycholate (d-AmB) was the standard antifungal agent formerly, which has been replaced with Liposomal AmB (L-AmB) because of its renal toxicity. Posaconazole is recommended for salvage treatment 5, 6 and isavuconazole has been recently approved by the U.S. Food and Drug Administration for treatment of invasive mucormycosis infection. 7 The estimated mortality rate for mucormycosis is very high ranging from 40% to 70% even if treated. In this fatal disease, the impact of a delay of diagnostic procedure is significant, as this delays initiation of antifungal therapy and may influence outcomes in patients with invasive mucormycosis infections. 1 In addition, there is only one retrospective study of mucormycosis in Korean patients. 8 For this reason, we conducted a retrospective study to evaluate the impact of delayed diagnostic procedure, along with other clinical predictors of outcome in patients with invasive mucormycosis infection.
Materials and methods

Patients
The medical records of patients with proven invasive mucormycosis between November 2005 and February 2014 were retrospectively reviewed. Patients were included in the study if they met the criteria for proven invasive mucormycosis based on standardised consensus criteria. 9 Diagnosis of proven invasive fungal disease was obtained by histopathological demonstration of broad, ribbon-like, wide-angled branching, non-septate hyphae even in the absence of positive culture results, which are accompanied by evidence of tissue invasion of fungal hyphae. 10 Patients with cutaneous mucormycosis and patients who were transferred to other hospitals before the end of treatment were excluded. Patients with an indefinite pathological diagnosis between mucormycosis and aspergillosis were also excluded.
Data collections
Data were obtained from two tertiary care referral hospitals, Severance Hospital and Gang-nam Severance Hospital, which are 2000-bed and 800-bed universityaffiliated teaching hospitals in Seoul, Republic of Korea respectively. The following data were collected: host and microbiologic characteristics (e.g. site of involvement), risk factors for invasive mucormycosis infection (e.g. type of malignancy, neutropenia, solid organ transplant, haematopoietic stem cell transplant, corticosteroid use), history of diabetes mellitus, hypertension, or chronic kidney disease, Acute Physiology and Chronic Health Evaluation II score at diagnosis of mucormycosis infection, antifungal therapy (e.g. drug, date of initiation, duration of treatment), date of symptom onset, date of diagnostic procedure and adjunctive therapeutic modalities (e.g. surgery) and outcome of patient at 180 days after the diagnosis of mucormycosis was made.
Study definitions
Neutropenia was defined as a neutrophil count ≤500 cells ll À1 . Severe neutropenia was defined as a neutrophil count ≤100 cells ll À1 . The definition of severe lymphopenia was a lymphocyte count ≤100 cells ll À1 . Hyperglycemia was defined as a glucose level ≥200 md dl À1 . All parameters were assessed at the time of diagnosis. Recent immunosuppression was defined as significant corticosteroid administration (use of ≥300 mg of a prednisone equivalent within 1 month before diagnosis), or receipt of chemotherapy within 1 month of symptom onset. Malnutrition was defined as a serum albumin level ≤3 g dl À1 . Preexisting renal failure was defined as an estimated glomerular filtration rate ≤ 60 (ml min À1 per 1.73 m 2 ) for ≥7 days before the onset of infection. Infection site was classified as: sino-orbito-cerebral which includes isolated sinusitis, sino-orbital, and sinocerebral lesions, pulmonary, gastrointestinal and disseminated. Disseminated infection was defined as involvement of two or more non-contiguous lesions. The date of diagnosis was defined as the day on which a procedure (biopsy, surgery or culture) leading to the diagnosis of mucormycosis was performed. The outcome was all-cause mortality 180 days after diagnosis of invasive mucormycosis.
Statistical analysis
All variables are expressed as means AE SD, unless otherwise indicated. Categorical variables were compared by v 2 analysis and continuous variables with normal distributions were compared using Student's t-tests. We used Mann-Whitney U-tests to compare continuous variables with skewed distribution. The interval (days) from the onset of symptoms to the implementation of the diagnostic procedure was explored using an algorithm of maximisation of hazard ratio to identify the cut-off value and help to categorise the patients into two groups; one group comprised of patients who received early effective diagnostic procedures and the other who received delayed diagnostic procedures. Survival curves of patients who received early diagnostic procedures vs. delayed diagnostic procedures were plotted using the Kaplan-Meier method, and differences in survival rates between the groups were analysed using the log-rank test. A multivariate Cox Proportional Hazards Regression model was built using a forward stepwise method. Covariates with a P < 0.1 identified by univariate analysis were used in the stepwise method. All statistical tests were performed using SPSS Software for Windows, version 20.0 (IBM, Armonk, NY, USA) and SAS version 9.2 (SAS Institute, Cary, NC, USA). P-value <0.05 was considered to be statistically significant.
Results
Between November 2005 and February 2014, 32 patients were diagnosed with invasive mucormycosis infection. Two patients were excluded from analysis because they were transferred to other hospitals during the treatment period. Five patients with cutaneous mucormycosis and one patient with an indefinite pathological diagnosis of mucormycosis vs. aspergillosis were also excluded. The medical records of 24 patients were retrospectively reviewed. Basic characteristics of patients diagnosed with invasive mucormycosis infection are presented in Table 1 . The mean age of the patients was 62.8 years and there were 16 male patients (66.6%). The all-cause 180-day mortality rate was 50%. All of the patients had underlying comorbidities, the most common of which was diabetes mellitus (66.6%), followed by hypertension (54.1%) and recent immunosuppression (25%). The most common site of infection was the sino-orbitocerebral area (58.3%), followed by the lung (29.1%) and the gastrointestinal tract (16.6%). There were no cases of disseminated mucormycosis in this study. A total of 22 patients received antifungal therapy; the majority of patients received d-AmB (17/24, 70.8%) as their initial antifungal agent followed by L-AmB (16.6%) and fluconazole (12.5%). Two patients did not receive antifungal therapy, and instead underwent surgical treatment only. Surgery was performed in 16 patients (66.6%). There was no patient who received a combination of antifungal therapy in our data and there was only one patient who received granulocyte colony-stimulating factor simultaneously with antifungal therapy in the survival group. Over the study period, relatively even distribution of the incidence was observed. Table 2 shows risk factors associated with mortality in patients with invasive mucormycosis infection. The cut-off value of 16 days was established using an algorithm of maximisation of hazard ratio 11 and this was used to categorise the patients into two groups; one group comprised of patients who received early effective diagnostic procedures and the other who received delayed diagnostic procedures. Eleven patients (45.8%) underwent an early diagnostic procedure. Delayed diagnostic procedures (performed ≥16 days after symptom onset) did not affect the mortality rate 90 days after diagnosis, but were associated with a statistically significant increase in all-cause mortality 180 days after diagnosis compared with early diagnostic procedures ( Fig. 1) .
On univariate analysis, the factors identified as significantly associated with poor outcomes for patients with mucormycosis were time from the onset of Data are expressed as mean AE SD or number (%). 1 Mann-Whitney U test. 2 Fisher's exact test. 3 Pearson's v. 4 Recent immunosuppression was defined as (i) significant corticosteroids administration (≥300 mg of a prednisone equivalent within 1 month before diagnosis) or, (ii) chemotherapy treatment within 1 month of symptom onset.
symptoms to diagnostic procedure such as biopsy or surgery (P = 0.009), the period between the onset of symptoms and the beginning of treatment (P = 0.045) and delayed diagnostic procedure (P = 0.005). Renal failure and low platelet counts showed trends toward poor outcomes for patients with mucormycosis, though these did not reach statistical significances (P = 0.089, 0.065 respectively). On multivariate analysis, delayed diagnostic procedure was an independent predictor of 180-day allcause mortality in patients with mucormycosis (OR = 12.34; 95% CI, 1.43-10.64) ( Table 3 ).
Discussion
Invasive mucormycosis causes severe morbidity and mortality in immunocompromised patients. Early diagnosis is critical, and may improve outcomes and survival in management of mucormycosis. 12 Currently available antigen tests (i.e. 1,3-b-D-glucan assay, galactomannan) do not detect invasive mucormycosis. 2 Predisposing host factors for mucormycosis include diabetic ketoacidosis, prolonged corticosteroid therapy, persistent neutropenia, severe graft-versus-host disease, active haematologic malignancy and solid organ or haematopoietic stem cell transplantation. In addition, type 2 diabetes, uncontrolled hyperglycemia, intravenous drug users, patients with burns, trauma or surgical wounds, and exposure to voriconazole prophylaxis in immunosuppressed patients are also important contributing factors that increase the risk for mucormycosis infection. 12, 13 The clinical signs and symptoms of invasive mucormycosis are non-specific. Early detection of pulmonary or sinus lesions on CT often provides evidence suggestive of an invasive fungal process. 2, 12 Notwithstanding these predisposing factors and clinical presentations, a considerable number of clinicians are found to prescribe antifungal agents that are not effective for mucormycosis, particularly because it is difficult to discriminate between invasive mucormycosis and aspergillosis infection, the latter of which is far more common. 13, 14 Mucormycosis is a disease with a high mortality rate. In this study the 180-day all-cause mortality rate was 50%, which correlates with that of previous studies (47-84%). 2, 15 Roden et al. [15] analysed survival by decade, revealing that overall mortality rates improved from 84% in the 1950s to 47% in the Data are expressed as mean AE SD, median (interquartile range) or number (%). 1 Fisher's exact test. 2 Mann-Whitney U test. 3 Pearson's v.
1990s, though mortality due to mucormycosis has remained almost unchanged since the 1960s, when d-AmB was first introduced. A recent retrospective study in Italy reported a lower mortality rate (32%, 19/60) in patients presenting with mucormycosis between 2004 and 2007. This may be explained by differences in the type of initial antifungal agent used. In our study, d-AmB was the most commonly used initial antifungal drugs compared to L-AmB, which was used initially in majority of patients (73%, 44/60) in the study by Pagano et al. [16] The fact that L-AmB is less toxic and contributes to higher survival rate has been cited in another retrospective study in patients with leukaemia 17 and also in animal study. 18 Many previous studies have evaluated risk factors for mucormycosis. 1, 8, 15 In our study, renal failure and thrombocytopenia were associated with increased mortality rates, though they did not reach statistical significance (P = 0.089, 0.065 respectively). In agreement with our results, Roden et al. [15] reported renal failure to be an independent risk factor for mortality along with the disseminated disease on multivariate regression analysis. Lewis et al. [2] found creatinine clearance and thrombocytopenia to be the significant risk factors for poor outcomes in patients with pulmonary mucormycosis on univariate analysis. A hallmark of mucormycosis infection is the presence of extensive angioinvasion with vessel thrombosis and tissue necrosis, resulting in thrombocytopenia and coagulopathy, which are common in patients with mucormycosis. 3 The presence of thrombocytopenia may reflect the severity of mucormycosis infection, but considering the relatively small number of patients included in our study, further investigation in a larger study population is required to determine the relationship between thrombocytopenia and long-term outcomes in patients with mucormycosis.
In our study, we evaluated the impact of delayed diagnostic procedure on mortality in patients with mucormycosis. The delayed diagnostic procedure (≥16 days) was significantly associated with increased 180-day all-cause mortality. The total time between the onset of symptom and the diagnostic procedure was also identified as a statistically significant variable on univariate analysis. Multivariate analysis which accounted for the age of the patients revealed that delayed diagnostic procedure (≥16 days) was an independent predictor of 180-day all-cause mortality. Chamilos et al. [1] demonstrated that delayed antifungal therapy increases mortality in patients with haematologic malignancy that has invasive mucormycosis infection. They emphasised importance of not alone timely administration of antifungal agents, but also aggressive diagnostic strategies. The significance of rapid diagnosis is well known, but had not been identified in a statistical way. In this study, we have depicted the effects of delayed diagnostic procedure on long-term outcomes of patients with invasive mucormycosis infection. In this study, diagnostic procedure was defined as an initial approach to determine the aetiology of the infection, which could include both biopsy and surgical debridement. Of the 24 patients in the study, 11 patients (45%) underwent diagnostic procedure prior to antifungal treatment and 9 patients (37%) underwent surgical debridement as the initial diagnostic approach.
In agreement with this study, a prospective multicenter study by Pagano et al. [16] reported that the Figure 1 Kaplan-Meier probability of survival after the diagnosis of mucormycosis, according to the timing of diagnostic procedure (P = 0.012). Delayed diagnostic procedure was defined as biopsy or surgery ≥16 days after symptom onset, and early diagnostic procedure was defined as biopsy or surgery <16 days after symptom onset. survival of patients with mucormycosis was significantly correlated with surgical debridement along with antifungal treatment (L-AmB). In addition, Almyroudis et al. [19] reported that the favourable outcomes were associated with surgically accessible disease and early surgical intervention along with AmB administration in solid organ recipients. A more recent report by Sun et al. [20] also reported extensive early surgical debridement to be an independent predictor of successful therapy in solid organ transplant recipients with pulmonary or rhino-orbito-cerebral mucormycosis. As this study exhibits, a diagnostic procedure such as biopsy or surgical debridement often comes before initiations of antifungal treatment since clinical and radiological presentations are not completely specific for the diagnosis of invasive mucormycosis. 12 Timely debridement of necrotic tissue can reduce the extent of infecting moulds and improve the penetration of antifungal agents to the site of infection. 5 Therefore, considering both the rapid growth of Mucorales and the fact that 84% of patients with pulmonary mucormycosis receive ineffective therapy at the time of diagnosis, 21, 22 rapid initiation of diagnostic procedures including early surgical debridement appears to be an important strategy.
In a recent study, the rate of mucormycosis infections increased from 1997 to 2006 in at-risk populations. 23 And in the absence of reliable diagnostic tools except direct examination and culture of infected tissues, molecular approaches are being studied in expectation that these approaches may guide to earlier diagnosis and rapid, directed therapy. Molecular identifications using the internal transcribed spacer (ITS) region as a sequencing target are being widely explored. 24 There are reports of recent clinical cases which performed molecular analyses using polymerase chain reaction (PCR) targeting ITS and quantification of Mucorales DNA in order to diagnose invasive mucormycosis infection. 25, 26 From the earlier studies which performed PCR assays using tissue specimens, 27 various approaches are being studied in more accessible materials such as human plasma or bronchoalveolar lavage samples. 24, 28 Molecular identification methods mostly have limitations that they are usually expensive, lacking clinical validations in prospective clinical trials, cross reactivity and difficulties in verifying many strains which cause mucormycosis. 29 In a recent study, combining a semiquantitative method using high-resolution melt analysis and real-time quantitative PCR (RQ PCR) assays showed sensitivity and specificity of 100% and 93% respectively, and high negative predictive value (99%) in detecting mucormycetes. 30 Another study by Dolatabadi et al. [31] presented rolling circle amplification method which performed mucorales DNA amplification successfully, with no cross reactivity between species, high specificity of 100% and also with high sensitivity. 31 Utility of these methods should be further explored on prospective studies to overcome the previously mentioned limitations.
Our study had several limitations. First, this study was retrospective in nature, which limits the amount and type of information that could be gathered. Second, it was performed at only two institutions in one regional area although both are tertiary care teaching hospitals. Third, because of the small number of patients in our study, there was a limit to the number of variables that could be included in the multivariate analysis. Additionally, there were no mucormycosis species identified via culture, so the association between mucormycosis genus/species and outcomes of the patients could not be evaluated. Furthermore, although initial diagnostic approach often connotes diagnostic and therapeutic interventions simultaneously in real clinical practice, the fact that initial diagnostic procedure includes both biopsy and surgical debridement could have biased clinical outcomes of patients in this study.
In our study, we found that early diagnostic procedures (within 16 days of symptom onset) were associated with improved long-term survival of patients with invasive mucormycosis infection. Performing an early diagnostic procedure along with early surgical debridement and early antifungal treatment may ensure better outcomes in patients with invasive mucormycosis infection. We believe these results will be helpful in developing strategies for managing invasive mucormycosis infection, though additional prospective largescale studies are needed to identify reliable surrogate markers for early diagnosis.
